A Treatment Legacy Effect of Metformin in Obese Women With PCOS

University Medical Centre Ljubljana

Status

Completed

Conditions

PCOS

Treatments

Drug: Metformin

Study type

Observational

Funder types

Other

Identifiers

NCT04566718

MET prosp

Details and patient eligibility

About

Metformin has multiple health promoting effects and it may serve as a preventive measure for individuals who are at high risk for metabolic complications.

According to the latest international guidelines it should be considered as an adjunct therapy to lifestyle intervention in all overweight/obese women with PCOS, independently of their glucose homeostasis and menstrual regularity. However, there is no clear answer for how long metformin should be prescribed in this subset of women with PCOS and for how long the beneficial impact would sustain after treatment cessation.

The investigators compared the consequences of metformin withdrawal after long-term therapy as opposed to the consequences of metformin suspension after short term therapy in overweight/obese women with PCOS that had previously responded to metformin by means of moderate weight loss, improved menstrual frequency and sustained normal glucose homeostasis.

Enrollment

40 patients

Sex

Female

Ages

18 to 55 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

PCOS defined by the National Institute of Child Health and Human Development (NICHD) criteria
obesity with body mass index ≥ 30 kg/m2
normal glucose homeostasis at metformin treatment

Exclusion criteria